Agios Q4 2022 net income $36.5M on PYRUKYND revenue $4.3M; cash $1.1B

AGIOS PHARMACEUTICALS, INC.

2022-FY EPS reported -$4.23 revenue$14,240,000

PYRUKYND net revenue $4.3M in Q4 2022, $11.7M full year; 78 patients on therapy, up 39% QoQ.
Net income from continuing ops $36.5M in Q4 vs loss $98.6M in Q4 2021; full-year net loss $231.8M.
Cash, equivalents and marketable securities $1.1B as of Dec 31, 2022, down from $1.3B year-end 2021.
Completed enrollment in Phase 2 RISE UP sickle cell study; on track to complete Phase 3 thalassemia enrollment by mid-2023.
Appointed Tsveta Milanova as chief commercial officer; received EU and Great Britain approvals for PYRUKYND.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

AGIOS PHARMACEUTICALS, INC. reported the fourth quarter and year ended Dec. 31, 2022 results: revenue Net U.S. product revenue from sales of PYRUKYND® was $4.3 million for the fourth quarter of 2022, and $11.7 million for, net income Net income was $36.5 million for the fourth quarter of 2022 compared to a net loss of $98.6 million for the fourth quart.

Period: the fourth quarter and year ended Dec. 31, 2022
Revenue: Net U.S. product revenue from sales of PYRUKYND® was $4.3 million for the fourth quarter of 2022, and $11.7 million for
Net income: Net income was $36.5 million for the fourth quarter of 2022 compared to a net loss of $98.6 million for the fourth quart
Result: reported results

Exact text from the filing

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today reported business highlights and financial results for the fourth quarter and year ended Dec. 31, 2022.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

AGIOS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001439222-23-000037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.